Percheron Therapeutics Limited has released a press release.
Company Strategy Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Orphan Drug designation from FDA for ATL1103 in Acromegaly
- ATL1103 Higher Dose Study - Update
- ATL1103 Deed of Settlement, Termination and Transfer
- ATL1102 for MS FDA Response to Phase IIb Study Plans
- COR-004/ATL1103 Project Update
Later from Percheron Therapeutics
- Antisense Technology Update
- ATL1102 for Multiple Sclerosis - Update
- ATL1103 Granted Orphan Drug Designation in Europe
- Positive Results Achieved from ATL1103 Higher Dose Study
- Company Update
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics